Anti-SARS-CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2 : results from a prospective cohort study on COVID-19 vaccination
(2025) In Infectious Diseases 57(8). p.782-792- Abstract
BACKGROUND: In May 2023, the World Health Organization declared COVID-19 no longer a public health emergency. Despite successful vaccination campaigns, vaccines provide limited protection against transmission. Since general testing has been abandoned in most countries, alternative population surveillance methods to assess SARS-CoV-2 exposure are needed.
METHODS: N-antigen is a protein of the SARS-CoV-2 virus that is not present in the vaccines and hence may be a useful serological marker of infection. This study evaluated N-antigen antibodies as a marker of SARS-CoV-2 exposure in a vaccinated Swedish cohort. Serum samples were collected and analysed for N-antigen antibodies using the mesoscale system. Nonlinear mixed-effects model... (More)
BACKGROUND: In May 2023, the World Health Organization declared COVID-19 no longer a public health emergency. Despite successful vaccination campaigns, vaccines provide limited protection against transmission. Since general testing has been abandoned in most countries, alternative population surveillance methods to assess SARS-CoV-2 exposure are needed.
METHODS: N-antigen is a protein of the SARS-CoV-2 virus that is not present in the vaccines and hence may be a useful serological marker of infection. This study evaluated N-antigen antibodies as a marker of SARS-CoV-2 exposure in a vaccinated Swedish cohort. Serum samples were collected and analysed for N-antigen antibodies using the mesoscale system. Nonlinear mixed-effects model accounting for multiple measurements per individual was used to estimate the half-life of N-antigen antibodies.
RESULTS: A total of 3,202 participants (median age 31 years) were recruited from April 2021 to February 2022 from four vaccination centres in Skåne, Sweden. A total of 2,999 participants had at least one valid N-antigen antibody measurement. The estimated half-life of N-antigen antibodies was 59 days (95% CI: 55-64 days). The estimated 95% range of halves-lives were from 24 to 174 days. The repeated measurements of N-antigen antibody levels could accurately detect SARS-CoV-2 infection. A twofold increase had a sensitivity of 91%, whereas a 16-fold increase had a specificity of 91%, respectively. The area under the curve (AUC) for predicting infection was 0.88 [95% C.I. 0.86-0.90].
CONCLUSION: Repeated monitoring of N-antigen antibody levels may be a valuable tool for assessing SARS-CoV-2 exposure and thus aid in monitoring transmission thereby helping in guiding vaccination strategies.
(Less)
- author
- Rasmussen, Magnus
LU
; Neumann, Ariane LU
; Moghaddassi, Mahnaz LU ; Inghammar, Malin LU ; Björk, Jonas LU
; Malmqvist, Ulf LU and Kahn, Fredrik LU
- organization
-
- Infect@LU
- Translational infection medicine (research group)
- Infection Medicine (BMC)
- Department of Clinical Sciences, Lund
- Social Medicine and Global Health (research group)
- Department of Clinical Sciences, Malmö
- EpiHealth: Epidemiology for Health
- eSSENCE: The e-Science Collaboration
- Division of Occupational and Environmental Medicine, Lund University
- publishing date
- 2025-03-18
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, COVID-19/diagnosis, Antibodies, Viral/blood, Adult, Female, Male, SARS-CoV-2/immunology, Sweden/epidemiology, Prospective Studies, Middle Aged, COVID-19 Vaccines/immunology, Young Adult, Adolescent, Aged, Coronavirus Nucleocapsid Proteins/immunology, Vaccination, COVID-19 Serological Testing, Phosphoproteins, nucleocapsid antibodies, COVID-19, serology, SARS Cov-2, half-life
- in
- Infectious Diseases
- volume
- 57
- issue
- 8
- pages
- 11 pages
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:105000422864
- pmid:40100206
- ISSN
- 2374-4235
- DOI
- 10.1080/23744235.2025.2479139
- language
- English
- LU publication?
- yes
- id
- 42871ed8-3cfa-4c50-be07-972842c6520d
- date added to LUP
- 2025-09-22 09:07:06
- date last changed
- 2025-09-23 04:04:25
@article{42871ed8-3cfa-4c50-be07-972842c6520d, abstract = {{<p>BACKGROUND: In May 2023, the World Health Organization declared COVID-19 no longer a public health emergency. Despite successful vaccination campaigns, vaccines provide limited protection against transmission. Since general testing has been abandoned in most countries, alternative population surveillance methods to assess SARS-CoV-2 exposure are needed.</p><p>METHODS: N-antigen is a protein of the SARS-CoV-2 virus that is not present in the vaccines and hence may be a useful serological marker of infection. This study evaluated N-antigen antibodies as a marker of SARS-CoV-2 exposure in a vaccinated Swedish cohort. Serum samples were collected and analysed for N-antigen antibodies using the mesoscale system. Nonlinear mixed-effects model accounting for multiple measurements per individual was used to estimate the half-life of N-antigen antibodies.</p><p>RESULTS: A total of 3,202 participants (median age 31 years) were recruited from April 2021 to February 2022 from four vaccination centres in Skåne, Sweden. A total of 2,999 participants had at least one valid N-antigen antibody measurement. The estimated half-life of N-antigen antibodies was 59 days (95% CI: 55-64 days). The estimated 95% range of halves-lives were from 24 to 174 days. The repeated measurements of N-antigen antibody levels could accurately detect SARS-CoV-2 infection. A twofold increase had a sensitivity of 91%, whereas a 16-fold increase had a specificity of 91%, respectively. The area under the curve (AUC) for predicting infection was 0.88 [95% C.I. 0.86-0.90].</p><p>CONCLUSION: Repeated monitoring of N-antigen antibody levels may be a valuable tool for assessing SARS-CoV-2 exposure and thus aid in monitoring transmission thereby helping in guiding vaccination strategies.</p>}}, author = {{Rasmussen, Magnus and Neumann, Ariane and Moghaddassi, Mahnaz and Inghammar, Malin and Björk, Jonas and Malmqvist, Ulf and Kahn, Fredrik}}, issn = {{2374-4235}}, keywords = {{Humans; COVID-19/diagnosis; Antibodies, Viral/blood; Adult; Female; Male; SARS-CoV-2/immunology; Sweden/epidemiology; Prospective Studies; Middle Aged; COVID-19 Vaccines/immunology; Young Adult; Adolescent; Aged; Coronavirus Nucleocapsid Proteins/immunology; Vaccination; COVID-19 Serological Testing; Phosphoproteins; nucleocapsid antibodies; COVID-19; serology; SARS Cov-2; half-life}}, language = {{eng}}, month = {{03}}, number = {{8}}, pages = {{782--792}}, publisher = {{Taylor & Francis}}, series = {{Infectious Diseases}}, title = {{Anti-SARS-CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2 : results from a prospective cohort study on COVID-19 vaccination}}, url = {{http://dx.doi.org/10.1080/23744235.2025.2479139}}, doi = {{10.1080/23744235.2025.2479139}}, volume = {{57}}, year = {{2025}}, }